It has been reported that treatment with CCL17, a specific ligand of CCR4, promotes hematoma resolution through the CCR4/ERK/Nrf2/CD163 pathway, thereby, improving neurological function, which is associated with microglia-mediated erythrocyte phagocytosis and clearance of tissue debris (Deng et al., 2020). This evidence concerns the gene CD163 and hematoma.